Myristoyl-L-carnitine (chloride)
Code | Size | Price |
---|
TAR-T37359-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T37359-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Myristoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Plasma levels of myristoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.[1][2]
CAS:
173686-73-2
Formula:
C21H42ClNO4
Molecular Weight:
408.02
Purity:
0.98
SMILES:
[Cl-].CCCCCCCCCCCCCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C
References
Reuter, S.E., and Evans, A.M. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J. Intern. Med. 270(1), 76-84 (2011).
Reuter, S.E., Evans, A.M., Faull, R.J., et al. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Ann. Clin. Biochem. 42(Pt 5), 387-393 (2005).